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 Marfan syndrome (MFS) is a connective tissue disorder that affects multiple 
organ systems. Cardiovascular, ocular, and skeletal abnormalities are 
cardinal features of the syndrome. Its incidence is among the highest of any 
heritable disorder.Most patients who have Marfan syndrome are usually 
diagnosed incidentally when they present for a routine physical examination 
for various reasons. The purpose of this paper is to provide a review of the 
literature, as well as describe a 22-year-old male with MFS and right 
hydroureteronephrosis diagnosed incidentally when he attended our hospital 
for complaints of fever and right loin pain. This case report emphasizes 
importance of “Revised Ghent criteria” for the diagnosis of MFS and 
highlights various clinical signs of MFS. 
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1. INTRODUCTION 
Marfan syndrome, a rare autosomal dominant disorder was first reported way back in 1896 by a 
French pediatricianAntonin Marfan. The prevalence is about 1:5000 [1]. MFS was characterized by 
Musculoskeletal features, include stature greater than 95percentile and limbs disproportionately long for 
trunk size (arachnodactyly), scoliosis, pectus excavatum or carinatum, higharched palate, flat feet and 
marked laxity of joints. Ocular features include non -progressive upward subluxation of lens and myopia. 
Cardiovascular manifestations include mitral valve prolapse and dilatation of ascending aorta which lead to 
mitral or aortic regurgitation. The diagnosis is made based on Revised Ghent criteria for the diagnosis of 
Marfan syndrome (MFS) and related conditions [2]. 
 
 
2. CASE PRESENTATION 
A 22 year old Indian male presented to our hospitalwith complaints of right loin pain since 3 weeks 
and fever since 2 weeks. His past and personal history was insignificant, but his mother had sudden death at 
the age of 39 years due to an undiagnosed cardiac problem. On general examination, he was lean, tall and the 
build of the patient is ectomorph as shown in (Figure 1). His height was 177cm, weight 44 kg and the 
calculated BMI 13.72 (kg/m2). He has long arms and long slender fingers (arachnodactyly) present. His arm 
span to total height ratio-1.10 (>1.05), meets the MFS diagnostic criteria.His Uppersegment length- 80cms, 
Lower segment length-97cms, US/LS ratio-0.82 (<0.85). There is positive thumb signor Steinberg sign as 
shown in (Figure 2) and positive wrist sign or walker sign as shown in (Figure 3). On examination of his oral 
cavity high arched palate was presentas shown in (Figure 4). There are multiple hypo pigmented macules 
over the hands as shown in Figures 3, 4 and also on foot of the patient. 
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On examination the temperature was 37.7oC, the pulse 102 beats per minute, the blood pressure 
110/70 mm Hg, the respiratory rate 20 breaths per minute and the oxygen saturation 98% with room air. 
Cardio vascular systemic examination revealed a mid systolic click with a late systolic murmur on 
auscultation. There was tendernessover the right loin of the patient. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Showing tall and lean patient with an 
ectomorph build and hypo pigmented macules 
over fore arm 
Figure 2. Showing thumb crossing the ulnar boarder of 
the hand , the Thumb sign or Steinberg sign 
Figure 3. This image shows the Walker-Murdoch 
(Wrist) sign. The sign is defined as overlap of the 
distal phalanges of the thumb and fifth finger when 
encircling the opposite wrist. It is indicative of 
arachnodactyly or abnormally long and slender 
fingers 
Figure 4. Showing High arched palate in this 
MFS patient 
Figure 5. shows a superior and nasal subluxation of 
lens in the left eye( Ectopia Lentis present), on slit 
lamp examination 
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In our present case there was no documented family history of MFS, Ectopia Lentis (EL) was 
present, the Z score was 3.85 ( Ao ,Z ≥ 2)  and with a systemic score of 5 (>7). 
 
Table  1. Shows Laboratory data of the patient on the day of admission 
Variable Reference Range Our Admission, This Hospital 
Hemoglobin(g/dl) 13.5-17.5 12.8 
Hematocrit(%) 41-53.0 44 
White cell count(%) 4500-13000 12,200 
Differential count(%)   
Neutrophils 40-62 52 
Lymphocytes 27-40 35 
Monocytes 4-11 8 
Eosinophils 0-8 5 
Basophils 0-3 0 
Platelet count( per mm3) 1,50,000-4,00,000 2,15,000 
Erythrocyte sedimentation rate(mm/hr) 0-15 18 
Rheumatoid factor(IU/ml) <30 <30 
HIV-1 and HIV-2 antibodies Non Reactive Non Reactive 
C- Reactive protein (mg/liter) <10 12 
 
 
Based on the history of right loin pain for 3 weeks and fever for 2 weeks the patient was subjected to 
the following laboratory investigations to exclude renal pathology. 
Figure 6. Shows echocardiogram in parasternal long axis view, the aortic root (Ao) diameter 
measuring 4.02 cm as marked above 
Figure 7. Shows echocardiogram in four chamber view with Mitral vavle prolapse 
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Table 2. Shows Biochemistry report of the patient on the day of admission 
Variable Reference Range Our Admission, This Hospital 
Fasting Blood Glucose(mg/dl) 75-100 84 
2 Hour oral glucose tolerance test (mg/dl) <200 110  
Sodium(mmol/L) 136-146 134 
Potassium(mmol/L) 3.5-5 4 
Chloride (mmol/L) 102-109 104 
Blood urea(mg/dl) 7-20 17 
Serum creatinine(mg/dl) 0.5-1.5 0.99 
 
 
The laboratory data done on the day of admission as shown in Table 1 shows an elevated 
Erythrocyte sedimentation rate (ESR) and C-Reactive protein. The White cell count was in the upper limit as 
shown in Table 1. The biochemical analysis as shown in Table 2 showed no abnormality. Urine analysis 
showed microscopic hematuria and pyuria. Later urine culture showed the growth of Escherichia coli 
organisms. Next the patient was subjected to CT-Kidney, Ureters, Bladder (KUB) plain study (Figure 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The CT-KUB PLAIN STUDY of the patient showed mild right hydroureteronephrosis secondary to 
distal ureteric (3mm) and VUJ caliculi (6mm) obstruction as shown in (Figure 8). Finally the patient was 
diagnosed with Marfan Syndrome and right hydroureteroneohrosis. 
 
 
3. TREATMENT 
On the day of admission the patient was put on analgesics for proper pain management. After the 
diagnosis of MFS with right hydroureteronephrosis was made, endocarditis prophylaxis was started and he 
was referred to urology department.The patient had undergone ureteral stent placement and recovered 
symptomatically. He was referred back to the department of Internal Medicine for further management 
regarding MFS. The patient was started on β-blocker therapy which currently remains the standard of care 
[3]. As the patient has moderate aortic dilatation of 3.85cms (<5cms), both short-term and long-term β-
blockade improves aortic stiffness index and elasticity in patients with modest dilatation or less, [4],[5] a 
benefit not observed in patients with marked dilatation [6]. Our patient was clinically asymptomatic 
pertaining to cardiovascular system.The patient is advised regarding moderate restriction of physical activity. 
Annual evaluation was offered to clinically evaluate and also with echocardiography. 
 
 
 
 
Figure 8. Shows CT-KUB PLAIN STUDY of the patient with mild hydroureteronephrosis 
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4. DISCUSSION 
Most patients who have Marfan syndrome are usuallydiagnosed incidentally when they present for a 
routine physical examination for various reasons. As so in our case the patient consulted for the symptoms of 
right loin pain and fever, for which he was diagnosed initially with MFS.In our present case there was no 
documented family history of MFS,  the Z score was 3.85 ( Ao ,Z ≥ 2) with Ectopia Lentis(EL) and systemic 
score of only 5. According to the Revised Ghent criteria for the diagnosis of MFS a systemic score of > 7 
indicates systemic involvement. The systemic score of 5 in our present case is calculated based on the 
following findings: 
▪ Positive Wrist AND thumb sign –3 (Figures 2 and 3), 
▪ Mitral valve prolapse (all types) –1 (Figure 7) 
▪ Reduced US/LS AND increased arm/height AND no severe scoliosis –1  
A diagnosis of MFS without systemic involvement was made according to the “Revised Ghent 
criteria”, in the absence of a family history:  
 
Ao (Z ≥ 2) AND EL = MFS [2]. 
 
A complete description of Revised Ghent criteria for the diagnosis of Marfan syndrome (MFS) and 
related conditions is given in the following Table 3. Our diagnosis was made based on the above criteria. 
 
 
Table 3. Revised Ghent for the diagnosis of Marfan syndrome (MFS) and related conditions [2] 
In the absence of a family history:  
(1) Ao (Z ≥ 2) AND EL = MFS  
(2) Ao (Z ≥ 2) AND FBN1 = MFS  
(3) Ao (Z ≥ 2) AND Syst (≥7 points) = MFSa 
(4) EL AND FBN1 with known Ao = MFS  
EL with or without Syst AND with an FBN1 not known with Ao or no FBN1 = ELS  
Ao (Z <2) AND Syst (≥5) with at least one skeletal feature without EL = MASS  
MVP AND Ao (Z <2) AND Syst (>5) without EL = MVPS  
In the presence of a family history:  
(5) EL AND FH of MFS (as defined above) = MFS  
(6) Syst (≥ 7 points) AND FH of MFS (as defined above) = MFS 
(7) Ao (Z ≥ 2 above 20 years old, ≥ 3 below 20 years) + FH of MFS (as defined above) = MFSa 
Systemic score  
▪ Wrist AND thumb sign –3 (Wrist OR thumb sign –1)  
▪ Pectus carinatum deformity –2 (pectus excavatum or chest asymmetry –1)  
▪ Hindfoot deformity –2 (plain pes planus –1)  
▪ Pneumothorax –2  
▪ Dural ectasia –2  
▪ Protrusio acetabuli –2  
▪ Reduced US/LS AND increased arm/height AND no severe scoliosis –1  
▪ Scoliosis or thoracolumbar kyphosis –1  
▪ Reduced elbow extension –1  
▪ Facial features (3/5) –1 (dolichocephaly, enophtalmos, downslanting palpebral fissures, malar hyoplasia, retrognathia)  
▪ Skin striae –1  
▪ Myopia > 3 diopters –1  
▪ Mitral valve prolapse (all types) –1  
Maximum total: 20 points; score ≥ 7 indicates systemic involvement. 
Ao, aortic diameter at the sinuses of Valsalva above indicated Z-score or aortic root dissection; EL, ectopia lentis; ELS, 
ectopia lentis syndrome; FBN1, fibrillin-1 mutation; FBN1 not known with Ao, FBN1 mutation that has not previously been 
associated with aortic root aneurysm/dissection; FBN1 with known Ao, FBN1 mutation that has been identified in an 
individual with aortic aneurysm; FH, family history; MASS, myopia, mitral valve prolapse, borderline (Z < 2) aortic root 
dilation, skeletal findings, striae; MFS, Marfan syndrome; MVPS, mitral valve prolapse syndrome; Syst, systemic score; 
US/LS, upper segment/lower segment ratio; Z, Z-score. 
aCaveat: without discriminating features of Shprintzen-Goldberg syndrome (SGS), Loeys-Dietz syndrome (LDS) or vascular 
Ehlers-Danlos syndrome (vEDS) AND after TGFBR1/2, collagen biochemistry, COL3A1 testing if indicated. Other 
conditions/genes will emerge with time. 
 
 
More than 90% of patients classified as having MFS have a  mutation in the gene encoding fibrillin 
(FBN1, chromosome 15q15–21.3) [7], a glycoprotein that is an integral part of the connective tissue in the 
body.Also, a few MFS patients without mutations in the FBN1 gene have mutations in the gene for TGF-β 
receptor 2 (TGFβR2). TGF-β was implicated in MFS following recent observation of its dysregulated 
signaling in fibrillin-1 deficient mice whereby antagonists of TGF-β decreased apoptosis and rescued lung 
defects [8]. The high levels of circulatingTGF-β in MFS patients [9], which incidentally ameliorated 
following treatment with losartan (an angiotensin II receptor blocker; ARB with TGF-β antagonistic 
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properties) [10], thus supporting TGF-β as a therapeutic target and potential biomarker for MFS. So 
treatment of MFS with losartan appears to be promising based on studies in animal models and is undergoing 
clinical trails. 
 
 
5. CONCLUSION 
Most patients who have Marfan syndrome are usuallydiagnosed incidentally when they present for a 
routine physical examination for various reasons. This case report brings forth the review of various clinical 
signs of MFS, its diagnosis based on the Revised Ghent criteria, its management and the associated comorbid 
conditions. 
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